Indeed, when the authors administered an adjuvant (i.e., poly I:C) to activate cDC1s in poorly radioimmunogenic tumor models, they observed greatly enhanced therapeutic efficacy in concert with IR in a manner dependent on cDC1s and CD8+ T cells [89]. The gene discussed is CD8A; the disease is neoplasm.